Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

  Sip Protocol

Masonic Cancer Research Center
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Back to Search Instructions

Protocol No. 2005LS048 Principal Investigator Bachanova, Veronika
Phase Phase II
Age Group Both Scope Local
Secondary Protocol No. MT2004-24
Title MT2004-24 Autologous Peripheral Blood Stem Cell Transplant for Patients with Lymphoma
Objective This trial is studying how well autologous peripheral stem cell transplant works in treating patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma.
Treatment The study involves patient's blood stem cell collection, chemotherapy before and after transplant, with or without radiation, and stem cell transplant. After completion of study treatment, patients are followed periodically.
Description Drugs used in chemotherapy, such as ifosfamide, etoposide, and carboplatin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving colony-stimulating factors, such as G-CSF, helps stem cells move from the patient's bone marrow to the blood so they can be collected and stored for peripheral stem cell transplant. Giving more chemotherapy, such as cyclophosphamide, carmustine, and etoposide, and total-body irradiation prepares the patient's bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy and radiation therapy. More radiation therapy is given after transplant to kill any remaining cancer cells.
Key Eligibility Patients diagnosed with Hodgkin's Lymphoma and Non Hodgkin's Lymphoma are eligible. Patients with HIV infection are eligible.
Applicable Disease Sites Hodgkin's Lymphoma
Lymphoid Leukemia
Non-Hodgkin's Lymphoma
Therapies Involved Blood and Marrow Transplant
Chemotherapy
Total Body Irradiation (TBI)
Drugs Involved BCNU (CARMUSTINE, BICNU)
CYCLOPHOSPHAMIDE (CYTOXAN, NEOSAR)
CYTOXAN (CYCLOPHOSPHAMIDE)
ETOPOSIDE (VP-16)
Status Open
Participating Institutions Masonic Cancer Center
Detailed Eligibility Patient must be no more than 75 years of age. Adequate organ function is required. Women who are pregnant or nursing are not eligible. Patients who are eligible for any higher priority transplant protocols and patients with chemotherapy resistant disease are not eligible. A signed informed consent and HIPAA authorization are required; assent form is also required if patient is a minor.
Treatment Type Treatment
Contact Timothy Krepski Phone:612-273-2800
Email:tkrepsk1@fairview.org